作者
Nicolas A Nunez, Balwinder Singh, Francisco Romo‐Nava, Boney Joseph, Marin Veldic, Alfredo Cuellar‐Barboza, Alejandra Cabello Arreola, Jennifer L Vande Voort, Paul Croarkin, Katherine M Moore, Joanna Biernacka, Susan L McElroy, Mark A Frye
发表日期
2020/3
来源
Bipolar disorders
卷号
22
期号
2
页码范围
109-120
简介
Objective
The aim of this study was to evaluate the efficacy and safety of the dopaminergic‐enhancing agent modafinil/armodafinil (MoArm) as adjunctive treatment for bipolar depression.
Methods
A comprehensive search of major electronic databases was conducted to identify randomized controlled trials (RCTs) of adjunctive MoArm that included patients with bipolar I (BP‐I) or bipolar II (BP‐II) depression. Data for response/remission and all‐cause discontinuation were analyzed. Effect size was summarized by relative risk (RR) using a random effect model.
Results
Of 58 studies, five RCTs (N = 795 drug, N = 792 placebo) met inclusion criteria. Four armodafinil studies included only BP‐I patients and one modafinil study included both bipolar subtypes with limited heterogeneity (I2 = 34%, P = .19; I2 = 18%, P = .30). Compared to placebo, augmentation with MoArm was associated with significantly greater rates …
学术搜索中的文章
NA Nunez, B Singh, F Romo‐Nava, B Joseph, M Veldic… - Bipolar disorders, 2020